Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HerinCAR-PD1 in EGFR+ Advanced Solid Tumors
NCT02873390Phase 2Unknown
- Sponsor
- Ningbo Cancer Hospital
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HerinCAR-PD1 cells in solid tumor (advanced stage), sponsored by Ningbo Cancer Hospital. Primary endpoints: Objective Response Rate at 2 years, Disease Control Rate at 2 years and 2 more. Status: unknown.
02
Drugs
HerinCAR-PD1 cells
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02873390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873390.